Skip to main content
ARQT
NASDAQ Life Sciences

Arcutis 10-Q: Q3 Revenue $143.9M, Nine-Month Profit $12.5M, ATM Upsized to $200M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$31.25
Mkt Cap
$4.28B
52W Low
$19.295
52W High
$34.8
52W Position info
62% above low
Off High info
10% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ARQT sits 62% above its 52-week low of $19.295.

Summary

Arcutis filed its Q3 2026 10-Q showing $143.9 million of product revenue, $12.5 million of nine-month net income and $259.8 million in cash, and disclosed a new $200 million at-the-market program alongside Robert Lisicki's permanent appointment as chief commercial officer.


Key Events · Earnings and Guidance · ARQT

  • Q3 Revenue Grows 45% to $143.9M

    Net product revenue of $143.9 million rose 45% from $99.2 million in Q3 2025, led by ZORYVE foam at $75.1 million (+51%).

  • Nine-Month Swing to $12.5M Profit

    Nine-month 2026 net income was $12.5 million versus a $33.5 million net loss a year earlier; Q3 net income was $8.8 million, or $0.06 diluted EPS.

  • ATM Capacity Doubled to $200M

    A November 4, 2026 amended sales agreement with TD Securities raises the at-the-market program to $200.0 million from $100.0 million; no shares have been sold under either agreement.

  • Cash Covers At Least 12 Months

    Cash, cash equivalents, restricted cash and marketable securities totaled $259.8 million at September 30, 2026, against $100.0 million of term debt outstanding.


Analysis · ARQT · Life Sciences

Two items in this quarterly report go beyond the same-day earnings release: a doubling of the at-the-market program to $200 million and a permanent chief commercial officer. The ATM is capacity, not a sale — no shares have been issued under it — but it gives management a ready lever to raise cash while the stock trades at $31.25, and it sits alongside $259.8 million of cash and marketable securities that the company says funds at least 12 months of operations. The income statement also shows the cost of growth: SG&A jumped 60% to $99.6 million in the quarter on the 'Skin to Believe In' campaign and an expanded sales force, which is why Q3 net income of $8.8 million came in below Q2's $15.0 million despite revenue rising 11% sequentially.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARQT was trading at $31.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $19.30 to $34.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARQT - Latest Insights

ARQT
Nov 05, 2026, 11:52 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $26.96
Real-time Price: $27.15 info
Change: +$0.190 (+0.70%) info
Market Cap: $3.436B info
ARQT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.00
Real-time Price: $27.15 info
Change: -$1.85 (-6%) info
Market Cap: $3.436B info
ARQT
Nov 04, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.30
Real-time Price: $27.15 info
Change: -$5.15 (-16%) info
Market Cap: $3.436B info
ARQT
Nov 04, 2026, 4:00 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $34.23
Real-time Price: $27.15 info
Change: -$7.08 (-21%) info
Market Cap: $3.436B info
ARQT
Aug 20, 2026, 1:38 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.92
Real-time Price: $27.15 info
Change: +$2.23 (+9%) info
Market Cap: $3.436B info